173 related articles for article (PubMed ID: 33619600)
1. RADTHYR: an open-label, single-arm, prospective multicenter phase II trial of Radium-223 for the treatment of bone metastases from radioactive iodine refractory differentiated thyroid cancer.
Deandreis D; Maillard A; Zerdoud S; Bournaud C; Vija L; Sajous C; Terroir M; Leenhardt L; Schlumberger M; Borget I; Leboulleux S
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3238-3249. PubMed ID: 33619600
[TBL] [Abstract][Full Text] [Related]
2.
Parihar AS; Mittal BR; Kumar R; Shukla J; Bhattacharya A
Thyroid; 2020 Apr; 30(4):557-567. PubMed ID: 31870227
[No Abstract] [Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
Qiu ZL; Xue YL; Song HJ; Luo QY
Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
[TBL] [Abstract][Full Text] [Related]
5. Impact of 18F-FDG PET/CT on Clinical Management of Suspected Radio-Iodine Refractory Differentiated Thyroid Cancer (RAI-R-DTC).
Lodi Rizzini E; Repaci A; Tabacchi E; Zanoni L; Vicennati V; Cavicchi O; Pagotto U; Morganti AG; Fanti S; Monari F
Diagnostics (Basel); 2021 Aug; 11(8):. PubMed ID: 34441364
[TBL] [Abstract][Full Text] [Related]
6. [(68)Ga]DOTATATE PET/MRI and [(18)F]FDG PET/CT are complementary and superior to diffusion-weighted MR imaging for radioactive-iodine-refractory differentiated thyroid cancer.
Vrachimis A; Stegger L; Wenning C; Noto B; Burg MC; Konnert JR; Allkemper T; Heindel W; Riemann B; Schäfers M; Weckesser M
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1765-72. PubMed ID: 27059853
[TBL] [Abstract][Full Text] [Related]
7. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.
Saad F; Carles J; Gillessen S; Heidenreich A; Heinrich D; Gratt J; Lévy J; Miller K; Nilsson S; Petrenciuc O; Tucci M; Wirth M; Federhofer J; O'Sullivan JM;
Lancet Oncol; 2016 Sep; 17(9):1306-16. PubMed ID: 27473888
[TBL] [Abstract][Full Text] [Related]
8. Clinical, Pathological, and Molecular Profiling of Radioactive Iodine Refractory Differentiated Thyroid Cancer.
Shobab L; Gomes-Lima C; Zeymo A; Feldman R; Jonklaas J; Wartofsky L; Burman KD
Thyroid; 2019 Sep; 29(9):1262-1268. PubMed ID: 31319763
[No Abstract] [Full Text] [Related]
9. PET response assessment in apatinib-treated radioactive iodine-refractory thyroid cancer.
Wang C; Zhang X; Yang X; Li H; Cui R; Guan W; Li X; Zhu Z; Lin Y
Endocr Relat Cancer; 2018 Jun; 25(6):653-663. PubMed ID: 29618578
[TBL] [Abstract][Full Text] [Related]
10. Radium-223 in Asian patients with castration-resistant prostate cancer with symptomatic bone metastases: A single-arm phase 3 study.
Zhou T; Zhou F; Guo J; Shi H; Yao X; Guo H; Yuan J; Tian Y; Zhang X; Wang S; Jiang Y; Zou Q; Zhou D; Li H; Li F; Lee JL; Chen CH; Park SH; Ng QS; Ma J; Zheng R; Ding Q; Liu X; Li R; Krissel H; Wagner VJ; Sun Y
Asia Pac J Clin Oncol; 2021 Dec; 17(6):462-470. PubMed ID: 33051982
[TBL] [Abstract][Full Text] [Related]
11. Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial.
Subbiah V; Anderson PM; Kairemo K; Hess K; Huh WW; Ravi V; Daw NC; Somaiah N; Ludwig JA; Benjamin RS; Chawla S; Hong DS; Meric-Bernstam F; Ravizzini G; Kleinerman E; Macapinlac H; Rohren E
Clin Cancer Res; 2019 Jul; 25(13):3802-3810. PubMed ID: 30733229
[TBL] [Abstract][Full Text] [Related]
12. Early Structural, Biochemical, and Metabolic Responses to Anlotinib in Patients With Progressive Radioactive Iodine Refractory Differentiated Thyroid Cancer.
Sun D; Zhang X; Sun Y; Mu Z; Wang H; Zhang Y; Liang J; Lin Y
Endocr Pract; 2024 May; 30(5):456-464. PubMed ID: 38447630
[TBL] [Abstract][Full Text] [Related]
13. The relationship between the quantitative evaluation of thyroid bed uptake and the disappearance of accumulation in adjuvant radioactive iodine therapy for differentiated thyroid cancer.
Konishi K; Ishiba R; Ikenohira T; Asao T; Hirata M; Ohira K; Komatsu T; Sawada M; Tanahashi Y; Goshima S; Magata Y; Nakamura K
Ann Nucl Med; 2021 Feb; 35(2):159-166. PubMed ID: 33387279
[TBL] [Abstract][Full Text] [Related]
14. Prospective evaluation of (99m)Tc MDP scintigraphy, (18)F NaF PET/CT, and (18)F FDG PET/CT for detection of skeletal metastases.
Iagaru A; Mittra E; Dick DW; Gambhir SS
Mol Imaging Biol; 2012 Apr; 14(2):252-9. PubMed ID: 21479710
[TBL] [Abstract][Full Text] [Related]
15. Bone metastases from differentiated thyroid carcinoma: heterogenous tumor response to radioactive Iodine therapy and overall survival.
Jannin A; Lamartina L; Moutarde C; Djennaoui M; Lion G; Chevalier B; Vantyghem MC; Deschamps F; Hadoux J; Baudin E; Schlumberger M; Leboulleux S; Do Cao C
Eur J Nucl Med Mol Imaging; 2022 Jun; 49(7):2401-2413. PubMed ID: 35149914
[TBL] [Abstract][Full Text] [Related]
16. Comparison of 18F-FDG PET and bone scintigraphy in detection of bone metastases of thyroid cancer.
Ito S; Kato K; Ikeda M; Iwano S; Makino N; Tadokoro M; Abe S; Nakano S; Nishino M; Ishigaki T; Naganawa S
J Nucl Med; 2007 Jun; 48(6):889-95. PubMed ID: 17504877
[TBL] [Abstract][Full Text] [Related]
17. Evaluating radium-223 response in metastatic castration-resistant prostate cancer with imaging.
Iizuka J
Asia Pac J Clin Oncol; 2018 Nov; 14 Suppl 5():16-23. PubMed ID: 30489033
[TBL] [Abstract][Full Text] [Related]
18. Could [18]F-fluorodeoxyglucose PET/CT change the therapeutic management of stage IV thyroid cancer with positive (131)I whole body scan?
Piccardo A; Foppiani L; Morbelli S; Bianchi P; Barbera F; Biscaldi E; Altrinetti V; Villavecchia G; Cabria M
Q J Nucl Med Mol Imaging; 2011 Feb; 55(1):57-65. PubMed ID: 21285923
[TBL] [Abstract][Full Text] [Related]
19. 18F-FDG-PET/CT in Patients Affected by Differentiated Thyroid Carcinoma with Positive Thyroglobulin Level and Negative 131I Whole Body Scan. It's Value Confirmed by a Bicentric Experience.
Bertagna F; Albano D; Bosio G; Piccardo A; Dib B; Giubbini R
Curr Radiopharm; 2016; 9(3):228-234. PubMed ID: 27210819
[TBL] [Abstract][Full Text] [Related]
20. Donafenib in Progressive Locally Advanced or Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Results of a Randomized, Multicenter Phase II Trial.
Lin YS; Yang H; Ding Y; Cheng YZ; Shi F; Tan J; Deng ZY; Chen ZD; Wang RF; Ji QH; Huang R; Li LF
Thyroid; 2021 Apr; 31(4):607-615. PubMed ID: 32907500
[No Abstract] [Full Text] [Related]
[Next] [New Search]
